VEGFA and breast cancer: This treatment strategy is growing increasingly promising as a clinical trial of combination therapy with the VEGF inhibitor Cediranib and the PARP inhibitor Olaparib showed efficacy in a cohort of breast cancer patients, both with and without BRCA mutations [76].